Core Viewpoint - The article emphasizes the importance of conducting thorough research and independent verification before making investment decisions, highlighting the inherent volatility and risks associated with stock investments [2][3]. Group 1 - The article provides informational content but does not serve as an exhaustive analysis of any featured company [2]. - It clarifies that the financial models presented are based on the author's assumptions and are sensitive to input changes, which can significantly alter outputs [2]. - The predictions and opinions expressed reflect a probabilistic approach rather than absolute certainty, indicating the need for caution [2]. Group 2 - The article states that past performance is not a guarantee of future results, underscoring the unpredictability of investment outcomes [3]. - It notes that no recommendations or advice are provided regarding the suitability of investments for particular investors [3]. - The authors of the article include both professional and individual investors, some of whom may not be licensed or certified [3].

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team ...

Core Insights - Ovid Therapeutics Inc. has reported earnings and revenue that surpassed estimates, indicating strong operational momentum and improving financial health [3][4][6] Company Overview - Ovid Therapeutics is a biopharmaceutical company focused on developing treatments for rare neurological disorders and brain conditions with significant unmet needs [2] - The company operates within the Zacks Medical - Biomedical and Genetics industry, competing in the development of innovative therapies [2] Financial Performance - For Q4 2025, Ovid reported earnings per share of $0.06, exceeding the Zacks Consensus Estimate of a $0.10 loss, representing a substantial earnings surprise of approximately +158-161% [3][6] - The company's revenue for Q4 2025 was $718,000, significantly higher than pre-release estimates ranging from ~$13,000 to $80,000, showcasing strong growth [4][6] Financial Position - Ovid's financial position is supported by cash, cash equivalents, and marketable securities, bolstered by a private placement in October 2025, which raised approximately $81 million upfront [5][6] - This funding is expected to support key studies for drug candidates OV329 and OV4071 and sustain operations into the second half of 2028 [5] - The price-to-sales ratio is around 22x, indicating investor optimism regarding Ovid's future growth prospects in its differentiated neurological pipeline [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the Fiscal Year Ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-38085 __________________________________ Ovid Therapeutics Inc. FORM 10-K _________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 _________________________________ ...

Ovid Therapeutics (NASDAQ: OVID) stock rose by more than 18% as of 12 a.m. today. The biopharmaceutical company is devoted to developing medicines for people with epilepsy and other brain conditions, and today's rise follows some positive newsflow on its most exciting pipeline program, OV329. A next-generation treatment The company defines OV329 as a "next-generation GABA-aminotransferase (GABA-AT) inhibitor being developed as a potential medicine for rare and treatment-resistant forms of epilepsy and sei ...

Epilepsy DataOvid Therapeutics reported favorable topline safety and tolerability findings from a 7 mg dose cohort of OV329 for drug-resistant epilepsies.There were no treatment-related adverse events in the 7 mg cohort, and 19 unrelated adverse events, all of which were mild and transient.Additionally, the company plans to expand OV329’s development to include tuberous sclerosis complex seizures and infantile spasms, with a proof-of-concept study for TSC expected to begin in the fourth quarter of 2026.The ...

Ovid Therapeutics (NasdaqGS:OVID) Q4 2025 Earnings call March 18, 2026 08:30 AM ET Company ParticipantsAlyssa Larios - Senior Associate in Equity ResearchJeffrey Rona - Chief Business and Financial OfficerMeg Alexander - President and CEOVictoria Fort - SVP of Corporate Affairs and Corporate StrategyConference Call ParticipantsFrançois Brisebois - Managing Director in Equity Research and Senior Biotechnology AnalystJay Olson - Managing Director in Equity Research and Senior Biotechnology AnalystLaura Chico ...

Financial Data and Key Metrics Changes - As of December 31, 2025, Ovid Therapeutics reported $90.4 million in cash equivalents and marketable securities [42] - The company announced a PIPE financing with gross proceeds totaling $60 million, which is expected to extend the cash runway into the second half of 2028 [42] - If the Series A warrants are fully exercised, the pro forma cash runway could extend well into 2029 [42] Business Line Data and Key Metrics Changes - The company received regulatory clearance for OV4071, the first-ever oral KCC2 direct activator, a quarter earlier than expected [5] - OV329, a next-generation GABA aminotransferase inhibitor, has shown no serious adverse events at the 7-milligram dose, indicating a strong safety and tolerability profile [5][13] - The company is launching additional studies for OV329 in infantile spasms and seizures associated with tuberous sclerosis complex, supported by new capital [7][8] Market Data and Key Metrics Changes - The market opportunity for OV329 is significant, especially in treating conditions like infantile spasms and tuberous sclerosis complex, where current treatment options are limited [24][27] - The peak sales of Sabril (Vigabatrin) reached over $320 million, indicating a substantial market potential for a safer alternative like OV329 [79] Company Strategy and Development Direction - Ovid Therapeutics aims to develop gentler, better medicines for the brain, focusing on controlling neural hyperexcitability through small molecule programs [9] - The company plans to initiate a phase 1 study for OV4071 and a ketamine challenge study to demonstrate proof of mechanism [33][40] - The strategy includes developing differentiated formulations for adult and pediatric populations, allowing for differential pricing based on the specific needs of each community [70] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of OV329 to be used earlier and longer in treatment, which could change the trajectory of diseases for children with severe conditions [78] - The company is optimistic about the upcoming milestones and catalysts, indicating a busy couple of years ahead [37] Other Important Information - Ovid Therapeutics does not plan to host regular quarterly earnings calls moving forward, indicating a shift in communication strategy [4] - The company is preparing for a KCC2 day to provide more insights into the KCC2 portfolio and its therapeutic potential [36] Q&A Session Summary Question: Can you provide more detail on OV329 and the visual monitoring? - Management confirmed that optic and retinal monitoring will continue through phase 2 and pivotal studies to ensure robust safety data [50] Question: What are the key endpoints for the planned phase two design for OV329? - The phase 2 study will target adults with treatment-resistant focal onset seizures, focusing on traditional endpoints like percent reduction in seizures and CGI endpoints [59] Question: What type of patients will be enrolled in the open-label photosensitive epilepsy study? - The study will enroll adults with diagnosed epilepsy and documented photosensitivity, using intermittent photic stimulation for screening [67] Question: How does the company plan to address long-term clinical development for OV329? - Management indicated that OV329 has broad therapeutic utility and that evidence will inform potential expansions into other indications [91]

Ovid Therapeutics (NasdaqGS:OVID) Q4 2025 Earnings call March 18, 2026 08:30 AM ET Speaker7Good afternoon, everyone. My name is Angela, and I will be your conference operator today. At this time, I would like to welcome you to Ovid Therapeutics Business and Pipeline Update Call. This conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speakers' prepared remarks, there will be a question-and-answer session. At this time, I would like to turn the call ov ...

Ovid Therapeutics (OVID) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +158.71%. A quarter ago, it was expected that this company would post a loss of $0.15 per share when it actually produced a loss of $0.17, delivering a surprise of -13.33%.Over the last four quarters, the ...